2. Search Result
Search Result
Results for "

G4-kappa

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

11

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P990089
    Patecibart

    Getagozumab; GMA-301

    		 Endothelin Receptor Cardiovascular Disease
    Patecibart is a humanized immunoglobulin G4-kappa, anti-EDNRA monoclonal antibody. Patecibart is an endothelin receptor antagonist .
    Patecibart
  • HY-P990074
    Enlonstobart

    SG-001

    		 PD-1/PD-L1 Inflammation/Immunology
    Enlonstobart is a human immunoglobulin G4-kappa, anti-PDCD1 monoclonal antibody. Enlonstobart is an immunostimulant and antineoplastic .
    Enlonstobart
  • HY-P990095
    Vonsetamig

    		CD3 TNF Receptor Inflammation/Immunology Cancer
    Vonsetamig is a humanised immunoglobulin G4-kappa, anti-TNFRSF17 and CD3E bispecific antibody. Vonsetamig is an antineoplastic .
    Vonsetamig
  • HY-P990092
    Rolistobart

    		Transmembrane Glycoprotein Cancer
    Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. Rolistobart is an immunostimulant and antineoplastic .
    Rolistobart
  • HY-P99510
    Zansecimab

    LY-3127804

    		 Tie Inflammation/Immunology Cancer
    Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, a monoclonal antibody against angiopoietin 2 (Ang 2). Zansecimab has potential applications in angiogenesis and immune regulation .
    Zansecimab
  • HY-P99767
    Olendalizumab

    ALXN1007; Lendalizumab

    		 Complement System Infection
    Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus .
    Olendalizumab
  • HY-P990068
    Perenostobart

    SRF617

    		 NTPDase Inflammation/Immunology Cancer
    Perenostobart (SRF617) is a human IgG4 antibody with inhibitory activity against CD39 ATPase. Perenostobart inhibits CD39-mediated hydrolysis of extracellular ATP to AMP, with IC50 values of 1.9 nM (HEK293 OE cells), 0.7 nM (MOLP-8 cells), and 1.2 nM (RBC-lysed whole blood). Perenostobart enhances CD4 + T-cell proliferation, promotes dendritic cell maturation, and boosts inflammasome activation in macrophages in the presence of ATP. Perenostobart demonstrates significant single-agent anti-tumor efficacy in MOLP-8 and H520 xenograft models. Perenostobart can be used for the study of cancer .
    Perenostobart
  • HY-P990073
    Davutamig

    REGN-5093

    		 c-Met/HGFR Cancer
    Davutamig (REGN-5093) is a humanIgG4-kappa, anti-MET bispecific antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic agent .
    Davutamig
  • HY-P991152
    Oturkibart

    QX-005N

    		 Interleukin Related Inflammation/Immunology
    Oturkibart is a humanized immunoglobulin G4-κ monoclonal antibody targeting the human interleukin 4 receptor (IL4R). Oturkibart is promising for research of inflammatory diseases, such as asthma and atopic dermatitis .
    Oturkibart
  • HY-P991137
    Exerenibart

    		Ser/Thr Protease Metabolic Disease
    Exerenibart is an immunoglobulin G4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .
    Exerenibart

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: